Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2022-12-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2023年度日常关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution regarding the expected daily related-party transactions for the year 2023 of a listed company. It includes transaction amounts, related parties, approval procedures by the board and supervisory committee, independent directors' opinions, and compliance with regulatory rules. The document is focused on related-party transactions and their expected amounts for the upcoming fiscal year, with no financial statements or quarterly results presented. It is not an announcement of voting results, nor a general regulatory filing or a report publication announcement. The content aligns with a regulatory or compliance report related to related-party transactions, which is typically filed as a Regulatory Filing (RNS) in the absence of a more specific category. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement or certification. Therefore, the best fit is Regulatory Filings (RNS).
2022-12-26 Chinese
成都先导药物开发股份有限公司关于向参股子公司转让项目、设备等暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Chengdu Lead Drug Development Co., Ltd. regarding a related-party transaction involving the transfer of projects, equipment, and licensing to its associate subsidiary. It details the transaction's background, pricing, approval by the board and independent directors, and compliance with regulatory rules. The document is a formal disclosure of a related-party transaction and does not contain financial statements or quarterly/annual report data. It is not a financial report, earnings release, or management discussion. It is a regulatory announcement about a corporate transaction involving related parties. Therefore, it fits best under Regulatory Filings (RNS). The document length is over 6,000 characters, so it is not a mere report publication announcement.
2022-12-26 Chinese
成都先导药物开发股份有限公司独立董事关于第二届董事会第八次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific board meeting proposals related to related-party transactions and daily related-party transaction amounts for 2022 and 2023. It references the second board meeting of the second board session held on December 26, 2022. The content focuses on governance and compliance with company rules and laws, expressing independent directors' views on board resolutions. It does not contain financial statements, audit results, or detailed financial data. It is not a full annual or interim report, nor an earnings release or capital update. The document is a governance-related statement tied to board meeting decisions, fitting the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2022-12-26 Chinese
成都先导药物开发股份有限公司关于2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2023. It details the approval process by the board and supervisory committee, the nature and amounts of the transactions, the related parties involved, and includes independent director opinions and sponsor institution verification. The document is a formal disclosure of anticipated related party transactions, not a financial report or audit. It is regulatory in nature, providing compliance information about related party dealings as required by stock exchange rules. The document length is 4572 characters, which is relatively short and focused on a specific announcement rather than a comprehensive report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-26 Chinese
成都先导药物开发股份有限公司关于向2021年限制性股票激励计划激励对象授予预留限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted shares under the company's 2021 restricted stock incentive plan. It includes information about the approval process, the number of shares granted, the grant price, the eligibility and conditions for the grant, accounting treatment, legal opinions, and financial advisor opinions. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not related to earnings releases, dividends, mergers, or management changes. The content focuses on the company's equity incentive plan and the granting of shares to employees and management, which is a capital/financing activity related to share issuance and stock-based compensation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-12-15 Chinese
成都先导药物开发股份有限公司监事会关于2021 年限制性股票激励计划预留授予激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the list of reserved grant recipients under the 2021 restricted stock incentive plan of Chengdu Lead Pharmaceutical Co., Ltd. It references relevant laws and regulations regarding stock incentive plans and confirms the eligibility of the incentive recipients. The document is short (1023 characters) and focuses on compliance and verification related to a stock incentive plan, not on financial results, management changes, or shareholder votes. It is not an announcement of a report but a formal opinion or verification statement related to stock incentives. This fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories like Capital/Financing Update or Director's Dealing.
2022-12-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.